The buy lands AbbVie with Landos’ lead asset NX-13, an oral NLRX1 agonist for ulcerative colitis (UC) and Crohn’s disease. Its mechanism of action is anti-inflammatory and facilitates epithelial repair, a natural function compromised in UC and Crohn’s. The Phase II candidate is already enrolling a UC trial in the U.S. and Europe.
AbbVie is dropping $20.42 per share, around $137.5 million in cash for Landos, a significant premium from the biotech’s Friday close price of $7.83. Shareholders will receive up to an additional $75 million total if certain clinical milestones are met. The deal is expected to close in the second quarter of 2024.
AbbVie’s other blockbuster on the market for UC is Rinvoq. The company is seeking approval to add the inflammatory bowel disease condition to Skyrizi’s indication list. Though sales of these two drugs haven’t yet come close to reaching Humira sales, even with last year’s market pressure from biosimilars.
The company’s blockbuster Humira lost exclusivity last year and is facing competition from biosimilars. AbbVie has been making deals and pushing new assets toward the market to try to lessen the steep patent cliff.
In February 2024, AbbVie struck a partnership with OSE Immunotherapeutics for the French biotech’s early-stage monoclonal antibody in chronic and severe inflammation. Paying $48 million upfront, AbbVie is on the line for $665 million in milestone payments. That same month, the pharma company paid $64 million for Tentarix’s Tentacles platform to work on two oncology and immunology programs. Also, two agreements were signed in January 2024 with Umoja for CAR-T therapies. Combined, the deals could yield up to $1.44 billion in payouts to Umoja.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Exploring Tau Protein’s Role in Glaucoma: New Insights and Therapeutic Potential
Glaucoma, a chronic neurodegenerative disorder, leads to irreversible vision loss by damaging retinal ganglion cells (RGCs) and the optic nerve, often associated with increased intraocular pressure (IOP). Despite the benefits of IOP-lowering treatments, the underlying...
FDA-mandated CAR-T monitoring period could be halved, say researchers
In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study...
Ancestral CRISPR-Cas13 Ribonucleases Discovered: Implications for Genome Editing
In a pioneering study published in *Science*, a team of researchers led by Peter H. Yoon and Jennifer A. Doudna from the University of California, Berkeley, has made a remarkable discovery in the realm of CRISPR technology. The team has identified an ancestral clade...
KBI Biopharma Expands Manufacturing Contract with Global Pharmaceutical Company
KBI Biopharma Inc., a JSR Life Sciences company and global cGMP contract development and manufacturing organization (CDMO), has extended and expanded its manufacturing contract with a leading global pharmaceutical company. Originally initiated in 2020, the renewed...
Related Services
Plasmids GMP Services
AAV GMP Services
